A. Ford

发表

Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis

F. Bazzoli, L. Eusebi, R. Ratnakumaran, 2017, Gut.

Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials.

A. Ford, A. Mikocka-Walus, H. Staudacher, 2021, The lancet. Gastroenterology & hepatology.

Longitudinal follow‐up of a novel classification system for irritable bowel syndrome: natural history and prognostic value

R. West, A. Ford, L. Houghton, 2021, Alimentary pharmacology & therapeutics.

Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease

A. Ford, K. Fairbrass, C. Selinger, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Prognosis of patients with Rome IV‐defined versus physician‐diagnosed irritable bowel syndrome: Longitudinal follow‐up study

A. Ford, Vivek C Goodoory, C. Black, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Natural History and Disease Impact of Rome IV versus Rome III Irritable Bowel Syndrome: A Longitudinal Follow-up Study.

A. Ford, L. Houghton, Vivek C Goodoory, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.

E. Savarino, A. Ford, L. Houghton, 2020, The American journal of gastroenterology.

Acceptability of a ‘treat to target’ approach in inflammatory bowel disease to patients in clinical remission

A. Ford, C. Selinger, J. Carbonell, 2020, Frontline Gastroenterology.

Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care

A. Ford, C. Black, D. Gracie, 2020, Gut.

Letter: Predictors of Dyspareunia Among Female Patients with Inflammatory Bowel Disease.

A. Ford, D. Gracie, A. O’Connor, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial.

F. Chan, A. Ford, P. Cheong, 2018, The lancet. Gastroenterology & hepatology.

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

M. Camilleri, A. Ford, D. Gracie, 2016, The American Journal of Gastroenterology.

High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria.

A. Ford, D. Sanders, Imran Aziz, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care

P. Moayyedi, A. Ford, M. I. Pinto-Sanchez, 2017, Alimentary pharmacology & therapeutics.

Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?

A. Ford, D. Vasant, 2020, World journal of gastroenterology.

Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

A. Ford, S. Halpin, Stephen J Halpin, 2012, The American Journal of Gastroenterology.

Response to Letter by Moulton et al.

P. Moayyedi, A. Ford, M. I. Pinto-Sanchez, 2019, Inflammatory bowel diseases.

Gastro‐oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South‐East Asian patients with dyspepsia

A. Axon, P. Moayyedi, A. Ford, 2005, Alimentary pharmacology & therapeutics.

The overlap of atopy and functional gastrointestinal disorders among 23 471 patients in primary care

A. Ford, N. Talley, M. Walker, 2014, Alimentary pharmacology & therapeutics.

Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case–control study of 23 471 primary care patients

A. Ford, N. Talley, M. Walker, 2014, Alimentary pharmacology & therapeutics.

Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

P. Moayyedi, M. Dubinsky, A. Ford, 2011, The American Journal of Gastroenterology.

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials.

P. Moayyedi, A. Ford, N. Talley, 2009, Diseases of the colon and rectum.

Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment

R. Spiller, W. Whitehead, K. Whelan, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

A. Ford, L. Peyrin-Biroulet, 2013, The American Journal of Gastroenterology.

Efficacy of Traditional Chinese Medicine in Functional Constipation

A. Ford, R. Whiting, 2011, The American Journal of Gastroenterology.

OBJECTIVES: Constipation is common in the community, and may affect survival adversely. An association between constipation and development of colorectal cancer (CRC) could be one possible explanation. We performed a systematic review and meta-analysis examining this issue.

A. Ford, N. Talley, A. Power, 2013 .

Association Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies

A. Ford, N. Talley, A. Power, 2013, The American Journal of Gastroenterology.

Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?

A. Ford, C. Davies, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same.

P. Moayyedi, A. Ford, 2011, Gastroenterology clinics of North America.

Irritable bowel syndrome.

A. Ford, P. Vandvik, 2019, BMJ clinical evidence.

Pathophysiology of irritable bowel syndrome.

A. Ford, N. Talley, G. Holtmann, 2016, The lancet. Gastroenterology & hepatology.

Irritable bowel syndrome : dietary interventions D ig estive system d iso rd ers

A. Ford, P. Vandvik, 2015 .

Irritable bowel syndrome: dietary interventions.

A. Ford, P. Vandvik, 2015, BMJ clinical evidence.

Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis

A. Ford, S. Thanaraj, P. Hamlin, 2010, Alimentary pharmacology & therapeutics.

Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow‐up study

Shujing Jane Lim, A. Ford, A. Scarsbrook, 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Macroscopic findings, incidence and characteristics of microscopic colitis in a large cohort of patients from the United Kingdom

A. Ford, J. Kane, O. Rotimi, 2017, Scandinavian journal of gastroenterology.

Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation

A. Ford, L. Houghton, C. Black, 2021, Alimentary pharmacology & therapeutics.

Systematic review with meta‐analysis: the efficacy of probiotics in inflammatory bowel disease

A. Ford, D. Gracie, P. Hamlin, 2017, Alimentary pharmacology & therapeutics.

Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.

A. Ford, A. Mikocka-Walus, D. Gracie, 2017, The lancet. Gastroenterology & hepatology.

Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence?

A. Ford, D. Gracie, A. Viggars, 2017, Gastroenterology.

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis.

A. Ford, J. Kane, Eline J C A Kamp, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Systematic review with meta‐analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease

A. Ford, D. Gracie, N. To, 2016, Alimentary pharmacology & therapeutics.

Systematic review with meta‐analysis: the effect of tobacco smoking on the natural history of ulcerative colitis

A. Ford, D. Gracie, N. To, 2016, Alimentary pharmacology & therapeutics.

Systematic review and meta‐analysis: opportunistic infections and malignancies during treatment with anti‐integrin antibodies in inflammatory bowel disease

A. Ford, P. Luthra, L. Peyrin-Biroulet, 2015, Alimentary pharmacology & therapeutics.

Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis

P. Moayyedi, G. Boeckxstaens, A. Ford, 2015, Gut.

Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis

P. Moayyedi, B. Spiegel, A. Ford, 2014, The American Journal of Gastroenterology.

The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis

P. Moayyedi, B. Spiegel, A. Ford, 2014, The American Journal of Gastroenterology.

Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation

P. Moayyedi, B. Spiegel, A. Ford, 2014 .

Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐α therapy in inflammatory bowel disease

A. Ford, L. Peyrin-Biroulet, C. J. Williams, 2014, Alimentary pharmacology & therapeutics.

Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis

A. Ford, P. Schoenfeld, D. Brenner, 2013, The American Journal of Gastroenterology.

Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.

P. Moayyedi, A. Ford, S. Hanauer, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Reporting of relapse rates in a trial of mesalazine for ulcerative colitis

A. Ford, A. Ford, 2010, Alimentary pharmacology & therapeutics.

Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis

Justin C.Y. Wu, A. Ford, H. Cramer, 2019, Therapeutic advances in gastroenterology.

Patient's Lower Gastrointestinal Tract Symptoms? This Establish That Irritable Bowel Syndrome Is Causing Will the History and Physical Examination Help

A. Ford, N. Talley, Sander J. O. Veldhuyzen, 2009 .

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

P. Moayyedi, A. Ford, D. Simel, 2008, JAMA.

A Systematic Review and Meta‐Analysis Evaluating the Efficacy of a Gluten‐Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome

P. Moayyedi, W. Chey, Yuhong Yuan, 2018, The American Journal of Gastroenterology.

Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.

A. Ford, P. Hamlin, S. Halpin, 2013, World journal of gastroenterology.

Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia.

P. Moayyedi, A. Ford, A. Marwaha, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.

D. Forman, P. Moayyedi, A. Ford, 2016, The Cochrane database of systematic reviews.

Errors in the Conduct of Systematic Reviews of Pharmacological Interventions for Irritable Bowel Syndrome

G. Guyatt, P. Moayyedi, A. Ford, 2010, The American Journal of Gastroenterology.

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, S. Hanauer, 2011, The American Journal of Gastroenterology.

Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis

L. Eusebi, A. Ford, C. Black, 2019, BMJ.

Letter: meta‐analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors’ reply

P. Moayyedi, A. Ford, E. Quigley, 2019, Alimentary pharmacology & therapeutics.

Efficacy of glutamine in postinfection IBS

A. Ford, P. Gibson, 2018, Gut.

cancer: systematic review and meta-analysis Diagnostic utility of alarm features for colorectal

P. Moayyedi, A. Ford, N. Talley, 2009 .

Clinical application of dietary therapies in irritable bowel syndrome.

K. Whelan, A. Ford, D. Sanders, 2018, Journal of gastrointestinal and liver diseases : JGLD.

British Society of Gastroenterology guidelines on the management of functional dyspepsia

A. Ford, L. Houghton, M. Corsetti, 2022, Gut.

Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.

M. Surette, P. Moayyedi, A. Ford, 2017, Gastroenterology.

Sporadic duodenal adenoma and colorectal neoplasia.

A. Ford, S. Everett, O. Rotimi, 2004, Gut.

Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom

A. Ford, C. Almansa, P. Moses, 2020, Gut.

Does Helicobacter pylori really cause duodenal ulcers? Yes

A. Ford, N. Talley, 2009, BMJ : British Medical Journal.

Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study.

D. Forman, A. Axon, P. Moayyedi, 2007, International journal of epidemiology.

H. pylori eradication therapy to prevent gastric cancer?

P. Moayyedi, Yuhong Yuan, A. Ford, 2004 .

Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases

M. Fassan, E. Savarino, A. Ford, 2021, Scientific Reports.

Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients.

D. Forman, P. Moayyedi, A. Ford, 2006, The Cochrane database of systematic reviews.

Helicobacter pylori eradication for the prevention of gastric neoplasia.

R. Hunt, D. Forman, P. Moayyedi, 2020, The Cochrane database of systematic reviews.

How to Read a Systematic Review and Meta‐Analysis

P. Moayyedi, A. Ford, 2014 .

Ulcerative colitis

P. Moayyedi, A. Ford, S. Hanauer, 2013, BMJ : British Medical Journal.

Epidemiology of Helicobacter pylori infection and Public Health Implications

A. Axon, A. Ford, 2010, Helicobacter.

randomised controlled trial ( MRC-CUBE trial ) dyspepsia in primary care : multicentre pump inhibitor in initial management of test and treat versus protonHelicobacter pylori

C. Mcnulty, P. Moayyedi, A. Ford, 2008 .

A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial.

D. Forman, A. Axon, P. Moayyedi, 2005, Gastroenterology.

Helicobacter pylori eradication: gastric cancer prevention.

A. Ford, G. Leontiadis, 2015, BMJ clinical evidence.

Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities

A. Ford, L. Houghton, C. Black, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Initial management strategies for dyspepsia.

D. Forman, P. Moayyedi, A. Ford, 2009, The Cochrane database of systematic reviews.

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility

M. Toruner, E. Savarino, A. Ford, 2022, United European gastroenterology journal.

Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation.

A. Ford, C. Black, N. Burr, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Is otilonium bromide globally effective in irritable bowel syndrome?

A. Ford, M. Desborough, 2011, Alimentary pharmacology & therapeutics.

Epidemiology of Dyspepsia

A. Ford, N. Talley, 2014 .

Current Guidelines for Dyspepsia Management

P. Moayyedi, A. Ford, 2008, Digestive Diseases.

Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study

D. Forman, A. Axon, P. Moayyedi, 2006, Gut.

Who Consults With Dyspepsia? Results from a Longitudinal 10-Yr Follow-Up Study

D. Forman, A. Axon, P. Moayyedi, 2007, The American Journal of Gastroenterology.

Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, J. Achkar, 2011, The American Journal of Gastroenterology.

Ipilimumab-induced colitis: experience from a tertiary referral center

A. Ford, M. Marples, A. O’Connor, 2016, Therapeutic advances in gastroenterology.

Functional dyspepsia.

A. Ford, N. Talley, B. Lacy, 2020, Lancet.

Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, C. Bernstein, 2011, The American Journal of Gastroenterology.

Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.

P. Moayyedi, M. Camilleri, Yuhong Yuan, 2019, The lancet. Gastroenterology & hepatology.

Clinical and epidemiological differences in functional dyspepsia between the East and the West

A. Ford, S. Mahadeva, 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review.

A. Ford, L. Keefer, C. Ko, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

This is a repository copy of Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network

Yuhong Yuan, A. Ford, C. Selinger, 2020 .

Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis

P. Moayyedi, A. Ford, D. Gracie, 2017, Alimentary pharmacology & therapeutics.

Global burden of irritable bowel syndrome: trends, predictions and risk factors

A. Ford, C. Black, 2020, Nature Reviews Gastroenterology & Hepatology.

Systematic review and meta‐analysis: efficacy of peppermint oil in irritable bowel syndrome

P. Moayyedi, A. Ford, G. Ianiro, 2022, Alimentary pharmacology & therapeutics.

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis

A. Ford, C. Black, D. Gracie, 2022, Gut.

The possible risks of proton pump inhibitors

A. Ford, D. Gracie, 2016, The Medical journal of Australia.

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis.

P. Moayyedi, W. Chey, A. Malhotra, 2009, Archives of internal medicine.

Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply

P. Moayyedi, A. Ford, G. Ianiro, 2022, Alimentary pharmacology & therapeutics.

This is a repository copy of Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome

L. Eusebi, A. Ford, G. Ianiro, 2020 .

Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis

A. Ford, D. Brenner, N. Burr, 2013, Gut.

Effect of gastro‐esophageal reflux symptoms on the risk of Barrett's esophagus: A systematic review and meta‐analysis

F. Bazzoli, L. Eusebi, A. Ford, 2022, Journal of gastroenterology and hepatology.

Dyspepsia

P. Moayyedi, A. Ford, 2013, Current opinion in gastroenterology.

GERD: Is laparoscopic surgery cost-effective?

A. Ford, 2009, Nature Reviews Gastroenterology &Hepatology.

Treatment of chronic gastro-oesophageal reflux disease

P. Moayyedi, A. Ford, 2009, BMJ : British Medical Journal.

Natural history and impact of irritable bowel syndrome‐type symptoms in inflammatory bowel disease during 6 years of longitudinal follow‐up

A. Ford, K. Fairbrass, D. Gracie, 2022, Alimentary pharmacology & therapeutics.

Cyclic vomiting syndrome: a case series and review of the literature

A. Ford, Pavit Luthra, J. Shearer, 2016, Frontline Gastroenterology.

The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions.

P. Moayyedi, A. Ford, P. Bercik, 2014, Gastroenterology.

Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic

A. Ford, U. Shivaji, 2014, Frontline Gastroenterology.

Initial management of dyspepsia in primary care: an evidence-based approach.

A. Ford, S. Ansari, 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

Dyspepsia

P. Moayyedi, A. Ford, 2013, BMJ.

Initial management of dyspepsia in primary care

A. Ford, S. Ansari, 2013 .

Effect of Dyspepsia on Survival: A Longitudinal 10-Year Follow-Up Study

D. Forman, A. Axon, P. Moayyedi, 2012, The American Journal of Gastroenterology.

Direction of the brain–gut pathway in functional gastrointestinal disorders

A. Ford, H. Whitehouse, 2012, Gut.

Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study.

A. Garg, P. Moayyedi, A. Ford, 2010, Gastroenterology.

Validation of the short-form leeds dyspepsia questionnaire (SF-LDQ) in a community setting

Susan R. Wilson, P. Moayyedi, A. Ford, 2003 .

Redundant Data in the Meta-analysis on Helicobacter pylori Eradication

P. Moayyedi, A. Ford, 2009, Annals of Internal Medicine.

Mycophenolate mofetil therapy for refractory inflammatory bowel disease

A. Ford, P. Hamlin, S. Everett, 2007, Inflammatory bowel diseases.

Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care

A. Ford, F. Bishop, R. Foy, 2019, Trials.

Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn

A. Ford, S. L. Marsden, Sarah L Marsden, 2016, The American Journal of Gastroenterology.

Treatment of Helicobacter pylori in Latin America

A. Ford, Claire M Slater, 2012, The Lancet.

Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Editorial: estimating the costs of care in irritable bowel syndrome—a necessary step to enhance value‐based care for a high‐prevalence, low‐cost condition. Authors' reply

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

This is a repository copy of Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III

A. Ford, L. Houghton, Y. Yiannakou, 2020 .

Making a positive diagnosis of irritable bowel syndrome.

A. Ford, R. Foy, R. Sood, 2017, The British journal of general practice : the journal of the Royal College of General Practitioners.

Editorial: latent class analysis to improve confidence in the diagnosis of IBS – authors’ reply

P. Moayyedi, A. Ford, D. Gracie, 2017, Alimentary pharmacology & therapeutics.

Editorial: volatile organic compounds in irritable bowel syndrome – technology for an accurate and reliable point‐of‐care test?

A. Ford, R. Sood, 2017, Alimentary pharmacology & therapeutics.

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterised by abdominal pain associated with a change in stool form and/or frequency.(1) The condition has an estimated prevalence of up to 20% in Western populations,(2)

A. Ford, D. Gracie, R. Sood, 2016 .

Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past

A. Ford, R. Sood, 2015, Clinical and Translational Gastroenterology.

Systematic review with meta‐analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers

A. Ford, D. Gracie, R. Sood, 2015, Alimentary pharmacology & therapeutics.

Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey

P. Moayyedi, A. Ford, P. Bercik, 2015, Scandinavian journal of gastroenterology.

Lack of Utility of Symptoms and Signs at First Presentation as Predictors of Inflammatory Bowel Disease in Secondary Care

P. Moayyedi, A. Ford, W. Reinisch, 2015, The American Journal of Gastroenterology.

Definitions and Classifications of Irritable Bowel Syndrome

A. Ford, 2013 .

Reply to Machicado JD, Villafuerte-Galvez J, Marcos LA, Prevalence of irritable bowel syndrome in South America.

A. Ford, R. M. Lovell, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Irritable bowel syndrome

A. Ford, N. Talley, 2012, BMJ : British Medical Journal.

21. Irritable Bowel Syndrome

P. Moayyedi, A. Ford, N. Talley, 2010 .

10‐biomarker algorithm to identify irritable bowel syndrome

P. Moayyedi, A. Ford, N. Talley, 2009, Alimentary pharmacology & therapeutics.

Functional Dyspepsia.

A. Ford, N. Talley, 2015, The New England journal of medicine.

Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.

A. Ford, S. Travis, S. Hanauer, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Irritable bowel syndrome.

A. Ford, P. Vandvik, 2012, BMJ clinical evidence.

systematic review and meta-analysis syndrome: oil in the treatment of irritable bowel Effect of fibre, antispasmodics, and peppermint

B. Spiegel, A. Ford, N. Talley, 2008 .

Title: A Novel Method to Classify and Subgroup Patients with IBS Based on Gastrointestinal Symptoms and Psychological Profiles. Short running head: Subgrouping People with IBS Using Symptoms and Psychological Profiles

A. Ford, L. Houghton, Y. Yiannakou, 2021 .

Editorial: subgroups in irritable bowel syndrome—more than just diarrhoea and constipation?

A. Ford, C. Black, 2017, Alimentary pharmacology & therapeutics.

The relationship between different information sources and disease‐related patient knowledge and anxiety in patients with inflammatory bowel disease

A. Ford, C. Selinger, D. Gracie, 2017, Alimentary pharmacology & therapeutics.

No increase in prevalence of somatization in functional vs organic dyspepsia: a cross‐sectional survey

P. Moayyedi, A. Ford, D. Gracie, 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating

P. Moayyedi, A. Ford, P. Bercik, 2015, Alimentary pharmacology & therapeutics.

Characteristics of functional bowel disorder patients: a cross‐sectional survey using the Rome III criteria

P. Moayyedi, A. Ford, P. Bercik, 2014, Alimentary pharmacology & therapeutics.

Peppermint Oil in Irritable Bowel Syndrome.

P. Moayyedi, A. Ford, C. Black, 2020, Gastroenterology.

Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.

P. Moayyedi, A. Ford, L. Houghton, 2018, Gastroenterology.

Glucocorticosteroid Therapy in Infl ammatory Bowel Disease: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, C. Bernstein, 2011 .

Effect of oral zinc in hepatic encephalopathy remains unclear

A. Ford, A. Ford, P. Hamlin, 2010, Alimentary pharmacology & therapeutics.

Is the Benefit of Granulocyte Monocyte Adsorptive Apheresis in Ulcerative Colitis Overstated?

A. Ford, S. Thanaraj, P. Hamlin, 2010, Digestive Diseases and Sciences.

review and meta-analysis therapies in irritable bowel syndrome: systematic Efficacy of antidepressants and psychological

P. Moayyedi, A. Ford, P. Schoenfeld, 2009 .

Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis

A. Ford, C. Selinger, A. O’Connor, 2016, Frontline Gastroenterology.

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.

A. Ford, P. Hamlin, D. Greer, 2011, Journal of Crohn's & colitis.

Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials.

E. Savarino, A. Ford, C. Black, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review

A. Ford, N. Talley, 2011, Journal of Gastroenterology.

General practitioners’ perceptions of irritable bowel syndrome: a Q-methodological study

A. Ford, R. Foy, S. Alderson, 2018, Family practice.

Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, J. Achkar, 2012, The American Journal of Gastroenterology.

Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, W. Sandborn, 2011, The American Journal of Gastroenterology.

Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, J. Achkar, 2011, The American Journal of Gastroenterology.

5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, N. Talley, 2011, The American Journal of Gastroenterology.

Mycophenolate mofetil in refractory inflammatory bowel disease

A. Axon, P. Moayyedi, A. Ford, 2003, Alimentary pharmacology & therapeutics.

Efficacy and tolerability of initiating, or switching to, inflixi mab biosimilar CT-P13 in Inflammatory Bowel Disease (IBD): A large single-centre experience

R. Ratnakumaran, A. Ford, C. Selinger, 2019 .

Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience

R. Ratnakumaran, A. Ford, C. Selinger, 2018, Scandinavian journal of gastroenterology.

Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.

A. Ford, P. Hamlin, S. Collins, 2014, Journal of Crohn's & colitis.

The Importance of Smoking Cessation in Improving Disease Course in Crohn’s Disease

A. Ford, D. Gracie, N. To, 2016, The American Journal of Gastroenterology.

Letter: deleterious effects of smoking on post‐operative Crohn's disease – authors’ reply

A. Ford, D. Gracie, N. To, 2016, Alimentary pharmacology & therapeutics.

Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease

A. Ford, D. Gracie, N. To, 2016, Alimentary pharmacology & therapeutics.

Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

M. Dubinsky, A. Ford, G. Radford-Smith, 2019, Inflammatory bowel diseases.

Effi cacy of Biological Therapies in Infl ammatory Bowel Disease: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, S. Hanauer, 2011 .

Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease

A. Ford, C. Selinger, D. Gracie, 2017, Inflammatory bowel diseases.

Efficacy and tolerability of methotrexate therapy for refractory Crohn’s disease: a large single‐centre experience

A. Ford, P. Hamlin, P. Hamlin, 2012, Alimentary pharmacology & therapeutics.

Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results

A. Ford, C. Selinger, D. Gracie, 2021, Inflammatory Intestinal Diseases.

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.

A. Ford, L. Peyrin-Biroulet, J. Colombel, 2013, Journal of Crohn's & Colitis.

Long-term efficacy and safety of azathioprine in ulcerative colitis.

A. Ford, P. Hamlin, R. Sood, 2015, Journal of Crohn's & colitis.

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.

A. Ford, J. Hamlin, D. Greer, 2012, Journal of Crohn's & colitis.

Hypertransaminasaemia and coeliac disease: authors’ reply

A. Ford, D. Sanders, A. Sainsbury, 2012 .

Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom

A. Ford, Vivek C Goodoory, C. Ng, 2022, Alimentary pharmacology & therapeutics.

Commentary: estimating the prevalence of IBS globally—past, present and future

A. Ford, 2020, Alimentary pharmacology & therapeutics.

Essential Medical Disorders of the Stomach and Small Intestine

A. Ford, M. Pimentel, B. Lacy, 2019, Springer International Publishing.

Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

P. Moayyedi, W. Chey, A. Ford, 2009, The American Journal of Gastroenterology.

Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial

J. Haughney, D. Mant, A. Ford, 2022, The Lancet.

Bloating and Abdominal Distention

A. Ford, L. Houghton, 2019 .

Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives.

A. Ford, C. Black, 2020, The American journal of gastroenterology.

Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease

A. Ford, K. Fairbrass, D. Gracie, 2020, Gut.

Evidence-based management of ulcerative colitis.

A. Ford, D. Gracie, 2012, Minerva gastroenterologica e dietologica.

Irritable bowel syndrome and somatization

A. Ford, P. Patel, 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysis

A. Ford, N. C. Suares, 2011, The American Journal of Gastroenterology.

A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship (PPR): A Rome Foundation Working Team Report.

D. Drossman, A. Ford, K. Kroenke, 2021, Gastroenterology.

Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis

A. Ford, C. Black, D. Gracie, 2021, Gut.

Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta‐analysis

E. Savarino, A. Ford, C. Black, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis

A. Ford, N. C. Suares, 2011, Gut.

Cyclic vomiting syndrome is a prevalent and under‐recognized condition in the gastroenterology outpatient clinic

A. Ford, D. Gracie, R. Sood, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

P. Moayyedi, B. Spiegel, A. Ford, 2008, BMJ : British Medical Journal.

Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.

A. Ford, L. Peyrin-Biroulet, W. Sandborn, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Efficacy of Fiber in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

P. Moayyedi, B. Spiegel, A. Ford, 2008 .

Comparison of acid‐lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta‐Analysis

E. Savarino, A. Ford, C. Black, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis

P. Moayyedi, A. Ford, R. Sood, 2014, Gut.

Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.

P. Moayyedi, A. Ford, P. Bercik, 2013, Gastroenterology.

Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis.

E. Savarino, A. Ford, B. Barberio, 2021, The lancet. Gastroenterology & hepatology.

Global Prevalence of Chronic Idiopathic Constipation According to the Rome Criteria: Systematic Review and Meta-Analysis

E. Savarino, A. Ford, B. Barberio, 2021 .

Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria.

E. Savarino, A. Ford, C. Black, 2020, Alimentary pharmacology & therapeutics.

Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.

E. Savarino, A. Ford, C. Black, 2020, The lancet. Gastroenterology & hepatology.

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

P. Moayyedi, A. Ford, P. Schoenfeld, 2008, Gut.

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

P. Moayyedi, A. Ford, L. Brandt, 2008, Gut.

Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior

D. Forman, A. Axon, P. Moayyedi, 2008, The American Journal of Gastroenterology.

The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review

P. Moayyedi, B. Spiegel, A. Ford, 2015, Clinical and Translational Gastroenterology.

American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation

P. Moayyedi, B. Spiegel, A. Ford, 2014, The American Journal of Gastroenterology.

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

A. Ford, R. M. Lovell, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies.

P. Moayyedi, A. Ford, J. Murray, 2017, Gastroenterology.

Population screening and treatment of Helicobacter pylori infection

C. O'Morain, A. Ford, A. O’Connor, 2017, Nature Reviews Gastroenterology &Hepatology.

Systematic review: the effects of fibre in the management of chronic idiopathic constipation

A. Ford, A. Ford, N. C. Suares, 2011, Alimentary pharmacology & therapeutics.

Prevalence of Gastro-Esophageal Reflux-Type Symptoms in Individuals With Irritable Bowel Syndrome in the Community: A Meta-Analysis

A. Ford, R. M. Lovell, 2012, The American Journal of Gastroenterology.

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

P. Moayyedi, W. Chey, A. Ford, 2018, American Journal of Gastroenterology.

Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.

M. Camilleri, A. Ford, E. Quigley, 2019, The lancet. Gastroenterology & hepatology.

Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management

A. Ford, C. Black, 2018, The Medical journal of Australia.

Pharmacotherapy for Irritable Bowel Syndrome

M. Camilleri, A. Ford, 2017, Journal of clinical medicine.

Chronic Constipation

W. Chey, M. Camilleri, A. Ford, 1928, Nature Reviews Disease Primers.

Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.

M. Camilleri, A. Ford, 2017, Handbook of experimental pharmacology.

Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome

A. Ford, R. Sood, 2013, Therapeutic advances in chronic disease.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

A. Ford, A. Farmer, L. Houghton, 2021, Gut.

Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome

P. Moayyedi, A. Ford, E. Quigley, 2018, Alimentary pharmacology & therapeutics.

Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis.

A. Ford, D. Sanders, A. Sainsbury, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prevalence of Primary Sclerosing Cholangitis in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

E. Savarino, A. Ford, B. Barberio, 2021, Gastroenterology.

Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, N. Talley, 2011, The American Journal of Gastroenterology.

Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.

A. Ford, K. Fairbrass, D. Gracie, 2020, The lancet. Gastroenterology & hepatology.

The Effect of Antidepressants on the Course of Inflammatory Bowel Disease

A. Ford, D. Gracie, P. Hamlin, 2018, Canadian journal of gastroenterology & hepatology.

Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.

E. Savarino, A. Ford, C. Black, 2021, The lancet. Gastroenterology & hepatology.

Histologic Criteria to Define Irritable Bowel Syndrome: Within the Realms of Possibility?

A. Ford, R. Sood, 2018, Gastroenterology.

Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

E. Savarino, A. Ford, C. Black, 2020, Journal of Crohn's & colitis.

Development and validation of a scoring system to identify patients with microscopic colitis.

A. Ford, J. Kane, S. Everett, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Diagnosis and treatment of irritable bowel syndrome.

A. Ford, N. C. Suares, 2011, Discovery medicine.

A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach

E. Savarino, A. Ford, B. Simionati, 2022, Gut microbes.

IBS-like symptoms in patients with ulcerative colitis

A. Ford, D. Gracie, 2015, Clinical and experimental gastroenterology.

Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation

K. Whelan, M. Fox, A. Ford, 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, E. Soffer, 2014, The American Journal of Gastroenterology.

Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus.

D. Forman, P. Moayyedi, A. Ford, 2005, American journal of epidemiology.

Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease

A. Ford, D. Gracie, P. Hamlin, 2016, The American Journal of Gastroenterology.

Masquerading gastrointestinal polyps: air on the side of caution? Cystic pneumatosis.

A. Ford, H. Cottom, O. Rotimi, 2014, Gastroenterology.

Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials

R. Hunt, D. Forman, P. Moayyedi, 2014, BMJ : British Medical Journal.

Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis

A. Ford, C. Black, H. Staudacher, 2021, Gut.

Systematic review with meta‐analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome

A. Gasbarrini, L. Eusebi, A. Ford, 2019, Alimentary pharmacology & therapeutics.

Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis

P. Moayyedi, M. Camilleri, A. Ford, 2019, Gut.

Effect of Gender on Prevalence of Irritable Bowel Syndrome in the Community: Systematic Review and Meta-Analysis

A. Ford, Alexander C Ford, Rebecca M Lovell, 2012, The American Journal of Gastroenterology.

Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms

P. Moayyedi, E. Savarino, A. Ford, 2020, Alimentary pharmacology & therapeutics.

Low Yield of Colonoscopy in Individuals With Suspected Irritable Bowel Syndrome?

A. Ford, 2010, The American Journal of Gastroenterology.

Applicability of the reported prevalence of bile salt malabsorption in irritable bowel

A. Ford, 2010, Alimentary pharmacology & therapeutics.

Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin

A. Ford, C. Selinger, D. Gracie, 2018, Therapeutic advances in gastroenterology.

Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease.

A. Ford, C. Selinger, A. O’Connor, 2018, Journal of Crohn's & colitis.

Antibiotic Therapy in Infl ammatory Bowel Disease: A Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, N. Talley, 2011 .

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis.

P. Moayyedi, B. Spiegel, A. Ford, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment.

A. Ford, D. Gracie, P. Hamlin, 2019, The lancet. Gastroenterology & hepatology.

Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

E. Savarino, A. Ford, C. Black, 2021, Journal of Crohn's & colitis.

Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?

A. Ford, R. Sood, G. Law, 2014, Nature Reviews Gastroenterology &Hepatology.

Efficacy of 5HT3-Antagonists in Non-Constipation Predominant Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

P. Moayyedi, W. Chey, A. Ford, 2008 .

Efficacy of Antidepressants in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, P. Schoenfeld, 2008 .

How can the current strategies for Helicobacter pylori eradication therapy be improved?

P. Moayyedi, A. Ford, 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

How can the current strategies for eradication therapy be improved

P. Moayyedi, A. Ford, 2003 .

Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis.

P. Malfertheiner, P. Moayyedi, A. Ford, 2008, World journal of gastroenterology.

Eradication Therapy in Helicobacter pylori Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis

D. Forman, P. Moayyedi, A. Ford, 2004, The American Journal of Gastroenterology.

Irritable bowel syndrome

M. Camilleri, A. Ford, A. Sperber, 2020, The Lancet.

R. West, A. Ford, L. Houghton, 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Rational investigations in irritable bowel syndrome

A. Ford, C. Black, 2019, Frontline Gastroenterology.

IBS in 2010: Advances in pathophysiology, diagnosis and treatment

A. Ford, N. Talley, 2011, Nature Reviews Gastroenterology &Hepatology.

High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment

A. Ford, J. Kane, O. Rotimi, 2018, Therapeutic advances in gastroenterology.

Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

A. Ford, J. Kane, 2016, Expert review of gastroenterology & hepatology.

Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents

A. Ford, A. Sainsbury, 2011, Therapeutic advances in gastroenterology.

The Efficacy of Probiotics in the Therapy of Irritable Bowel Syndrome (IBS): a Systematic Review

P. Moayyedi, A. Ford, L. Brandt, 2008 .

Recent developments in gastroenterology

P. Moayyedi, A. Ford, Paul Moayyedi, 2002, BMJ : British Medical Journal.

Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis

P. Moayyedi, Yuhong Yuan, A. Ford, 2020, Gut.

Letter: effects of iron therapy after non‐variceal acute upper gastrointestinal bleeding

A. Ford, E. Bounford, 2014, Alimentary pharmacology & therapeutics.

Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.

D. Drossman, A. Ford, J. Tack, 2017, Gastroenterology.

Longitudinal impact of IBS‐type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease

A. Ford, D. Gracie, J. Hamlin, 2018, The American Journal of Gastroenterology.

Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease

A. Ford, 2010, Gut.

Faecal microbiota transplantation for Clostridium difficile‐associated diarrhoea: a systematic review of randomised controlled trials

P. Moayyedi, Yuhong Yuan, A. Ford, 2017, The Medical journal of Australia.

Functional gastrointestinal disorders: advances in understanding and management

D. Drossman, A. Ford, N. Talley, 2020, The Lancet.

Letter: irritable bowel syndrome is significantly associated with somatisation – authors’ reply

A. Ford, P. Patel, 2015, Alimentary pharmacology & therapeutics.

Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics

H. Tilg, A. Gasbarrini, A. Ford, 2019, Annals of Internal Medicine.

Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis

Yuhong Yuan, A. Ford, K. Fairbrass, 2021, Gut.

Antidepressants in inflammatory bowel disease

D. Drossman, A. Ford, A. Mikocka-Walus, 2020, Nature Reviews Gastroenterology & Hepatology.

GI epidemiology: diseases and clinical methodology.

P. Moayyedi, A. Ford, J. West, 2014 .

Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis

W. Chey, A. Ford, A. Irvine, 2017, The American Journal of Gastroenterology.

Constipation in adults.

A. Ford, M. Lau, 2015, BMJ clinical evidence.

Chemoprevention for gastric cancer.

A. Ford, 2011, Best practice & research. Clinical gastroenterology.

The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study

A. Ford, A. Stengel, C. Bernstein, 2021, Journal of Psychosomatic Research.

Prevalence of Anxiety and Depression in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

E. Savarino, A. Ford, C. Black, 2021 .

Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis.

A. Ford, C. Black, D. Gracie, 2023, Inflammatory bowel diseases.

No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease.

A. Ford, P. Quirke, D. Gracie, 2018, Inflammatory bowel diseases.

Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome–type Symptoms in Patients With Inflammatory Bowel Disease

A. Ford, D. Gracie, R. Sood, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Response to Kayhan et al.

P. Moayyedi, A. Ford, 2012, The American Journal of Gastroenterology.

Longitudinal follow‐up study: effect of psychological co‐morbidity on the prognosis of inflammatory bowel disease

A. Ford, K. Fairbrass, D. Gracie, 2021, Alimentary pharmacology & therapeutics.

Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.

A. Ford, D. Gracie, J. Headlam, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?

A. Ford, D. Gracie, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency

P. Moayyedi, A. Ford, S. Collins, 2015, The American Journal of Gastroenterology.

Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.

A. Ford, E. Guthrie, D. Gracie, 2018, Gastroenterology.

Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease.

P. Moayyedi, A. Ford, W. Reinisch, 2019, Inflammatory bowel diseases.

Reply to Akobeng

P. Moayyedi, A. Ford, N. Talley, 2011, The American Journal of Gastroenterology.

NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people

A. Ford, A. Lobo, J. Mayberry, 2013, Alimentary pharmacology & therapeutics.

Fatigue and its associated factors in microscopic colitis

A. Ford, J. Kane, Y. Derwa, 2018, Therapeutic advances in gastroenterology.

Whom should we “test and treat” for Helicobacter pylori?

P. Moayyedi, A. Ford, 2014, BMJ : British Medical Journal.

Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care?

P. Moayyedi, A. Ford, 2009, Polskie Archiwum Medycyny Wewnetrznej.

Systematic review and network meta‐analysis: efficacy of drugs for functional dyspepsia

P. Moayyedi, Yuhong Yuan, A. Ford, 2020, Alimentary pharmacology & therapeutics.

Systematic review with meta‐analysis: association of Helicobacter pylori infection with gastro‐oesophageal reflux and its complications

L. Eusebi, A. Ford, A. Hasanpour, 2021, Alimentary pharmacology & therapeutics.

Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis.

P. Moayyedi, A. Ford, B. Delaney, 2005, Gastroenterology.

Editorial: Using Patient-Reported Outcome Measures in Gastroenterology: PROMISed Land or Road to Nowhere?

A. Ford, D. Gracie, 2016, The American Journal of Gastroenterology.

The Glasgow Prognostic Score at the Time of Palliative Esophageal Stent Insertion is a Predictive Factor of 30-Day Mortality and Overall Survival

M. Bennett, A. Ford, S. Everett, 2016, Journal of clinical gastroenterology.

Aetiopathogenesis of functional dyspepsia

A. Ford, 2015, Gut.

Ondansetron and irritable bowel syndrome

A. Ford, P. Luthra, 2014, Gut.

Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis.

A. Ford, C. Black, N. Mohammed, 2020, The lancet. Gastroenterology & hepatology.

Cyclic Vomiting Syndrome: Randomized Controlled Trials Are also Needed in Adults

A. Ford, R. Sagar, 2017, The American Journal of Gastroenterology.

Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials

A. Ford, S. Veettil, N. Chaiyakunapruk, 2021, British journal of clinical pharmacology.

Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis

L. Eusebi, A. Ford, R. Zagari, 2020, Gut.

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial)

C. Mcnulty, P. Moayyedi, A. Ford, 2009 .

Helicobacter pylori eradication for the prevention of gastric neoplasia.

R. Hunt, D. Forman, P. Moayyedi, 2020, The Cochrane database of systematic reviews.

Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis

P. Moayyedi, A. Ford, N. Talley, 2008, Gut.

Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis

P. Moayyedi, Yuhong Yuan, A. Ford, 2022, Gut.

Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis

P. Moayyedi, A. Ford, L. Houghton, 2020, Gut.

Diagnosis: Rome IV criteria for FGIDs — an improvement or more of the same?

A. Ford, R. Sood, 2016, Nature Reviews Gastroenterology &Hepatology.

Psychometric evaluation of an experience sampling method–based patient‐reported outcome measure in functional dyspepsia

A. Ford, Q. Aziz, N. Talley, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Development of a real‐time patient‐reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method

A. Ford, Q. Aziz, J. van os, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-up Study.

E. Savarino, A. Ford, L. Houghton, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Don’t forget about constipation with opioid treatment of chronic non-cancer pain

A. Ford, P. Schoenfeld, D. Brenner, 2013, BMJ.

Initial management strategies for dyspepsia (Withdrawn Paper. 2009, art. no. CD001961)

D. Forman, P. Moayyedi, A. Ford, 2009 .

Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome with Constipation or Diarrhea: Meta-Analysis.

E. Savarino, A. Ford, C. Black, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement.

A. Gasbarrini, A. Ford, G. Ianiro, 2020, Alimentary pharmacology & therapeutics.

Best management of irritable bowel syndrome

A. Ford, C. Black, 2020, Frontline Gastroenterology.

Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial

P. Whorwell, R. Spiller, J. Mclaughlin, 2019, Trials.

Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea.

A. Ford, C. Black, 2020, The American journal of gastroenterology.

Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea.

A. Ford, L. Houghton, C. Black, 2020, The American journal of gastroenterology.

Impact of Rome IV irritable bowel syndrome on work and activities of daily living

A. Ford, C. Ng, C. Black, 2022, Alimentary pharmacology & therapeutics.

Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome

A. Ford, L. Houghton, A. Mikocka-Walus, 2021, The American journal of gastroenterology.

A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.

R. West, A. Ford, L. Houghton, 2020, The American journal of gastroenterology.

Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria.

A. Ford, L. Houghton, C. Black, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Symbiotics in irritable bowel syndrome – better than probiotics alone?

A. Ford, D. Gracie, 2015, Current opinion in clinical nutrition and metabolic care.

Symbiotics in irritable bowel syndrome – better than probiotics alone?

A. Ford, D. Gracie, 2015, Current opinion in clinical nutrition and metabolic care.

Efficacy of linaclotide in irritable bowel syndrome with constipation: Real‐world data

A. Ford, P. Paine, A. Agrawal, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Functional dyspepsia

A. Ford, N. Talley, B. Lacy, 2020, The Lancet.

Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom‐Reporting Behavior Rather Than Biochemical Activity or Anemia

R. Ratnakumaran, A. Ford, D. Gracie, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis

P. Moayyedi, A. Ford, E. Quigley, 2019, The American journal of gastroenterology.

Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease?

A. Ford, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease

R. Ratnakumaran, A. Ford, D. Gracie, 2019, Therapeutic advances in chronic disease.

Letter: causes of fatigue in inflammatory bowel disease remain uncertain

A. Ford, D. Gracie, Alexander C Ford, 2017, Alimentary pharmacology & therapeutics.

Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 years of Longitudinal Follow-up.

A. Ford, K. Fairbrass, D. Gracie, 2022, Gastroenterology.

Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation?

A. Ford, D. Gracie, 2017, Inflammatory Bowel Diseases.

A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?

A. Ford, D. Gracie, 2017, Gastroenterology.

Defining the relationship between clinical and biochemical disease activity indices and perceived stress in inflammatory bowel disease.

A. Ford, D. Gracie, 2015, Gastroenterology.

Antibiotics and Probiotics for Irritable Bowel Syndrome

A. Ford, Vivek C. Goodoory, 2023, Drugs.

Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease—authors' reply

A. Ford, K. Fairbrass, D. Gracie, 2022, Alimentary pharmacology & therapeutics.

Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge.

A. Ford, D. Gracie, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?

A. Ford, D. Gracie, 2018, The American Journal of Gastroenterology.

Characteristics and Impact of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.: Anxiety and Depression Trajectories in IBD.

A. Ford, C. Black, E. Guthrie, 2022, The American journal of gastroenterology.

Insights into the evaluation and management of dyspepsia: recent developments and new guidelines

A. Ford, L. Houghton, C. Black, 2018, Therapeutic advances in gastroenterology.

Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes

P. Moayyedi, A. Ford, Laura Glenn, 2013, Gut.

Dyspepsia: Ulcer and Non‐Ulcer/Bloating and Early Satiety/Belching and Rumination

P. Moayyedi, A. Ford, 2012 .

Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients.

D. Forman, P. Moayyedi, A. Ford, 2006, The Cochrane database of systematic reviews.

Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive-Behavioral Therapy.

A. Ford, 2018, Gastroenterology.

Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders

A. Ford, L. Houghton, C. Black, 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Editorial: co‐morbid gastrointestinal conditions are an important consideration in IBS management—authors' reply

A. Ford, C. Black, 2021, Alimentary pharmacology & therapeutics.

Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply

A. Ford, C. Black, B. Barberio, 2021, Alimentary pharmacology & therapeutics.

Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux–Type Symptoms in the Community: A Systematic Review and Meta‐analysis

F. Bazzoli, L. Eusebi, R. Ratnakumaran, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach.

P. Nachev, A. Ford, A. Farmer, 2020, The American journal of gastroenterology.

Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.

F. Bazzoli, L. Eusebi, A. Ford, 2021, Alimentary pharmacology & therapeutics.

Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome

A. Ford, C. Ng, C. Black, 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease

A. Ford, James A. Eaden, 2012, Gut.

Response to Neis et al.

A. Ford, N. Talley, 2013, The American Journal of Gastroenterology.

Editorial: probiotics in inflammatory bowel disease—wrong organisms, wrong disease, or flawed concepts?

A. Ford, D. Gracie, P. Hamlin, 2017, Alimentary pharmacology & therapeutics.

Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia

P. Moayyedi, A. Ford, P. Bercik, 2017, Scandinavian journal of gastroenterology.

Review: Prevention and management of gastric cancer

P. Malfertheiner, T. Rokkas, A. Ford, 2020, Helicobacter.

British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome

P. Whorwell, R. Spiller, A. Forbes, 2000, Gut.

Antibiotic use and subsequent development of functional gastrointestinal disorders: effect of symptom‐reporting and consultation behavior

A. Ford, T. P. Bidmead, 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality

A. Ford, U. Shivaji, 2014, Primary Health Care Research & Development.

In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents

A. Ford, 2012, Evidence-Based Medicine.

Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome.

A. Ford, C. Black, 2022, Gastroenterology.

Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis.

A. Gasbarrini, A. Ford, G. Ianiro, 2023, Journal of autoimmunity.

Irritable bowel syndrome: a spotlight on future research needs.

A. Ford, C. Black, 2021, The lancet. Gastroenterology & hepatology.

AJG-20-4059 1485..1494

A. Ford, L. Houghton, C. Black, 2022 .

How effective are antibiotics for the treatment of irritable bowel syndrome?

A. Ford, C. Black, 2020, Expert opinion on pharmacotherapy.

Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?

A. Ford, D. Gracie, 2016, The American Journal of Gastroenterology.

Laxatives for chronic constipation in adults

A. Ford, N. Talley, 2012, BMJ : British Medical Journal.

Response to Yang et al.

P. Moayyedi, A. Ford, N. Talley, 2011, The American Journal of Gastroenterology.

Meta‐analysis: Helicobacter pylori‘test and treat’ compared with empirical acid suppression for managing dyspepsia

P. Moayyedi, A. Ford, B. Delaney, 2008, Alimentary pharmacology & therapeutics.

Meta‐analysis: factors affecting placebo response rate in the irritable bowel syndrome

P. Moayyedi, A. Ford, A. C. Ford, 2010, Alimentary pharmacology & therapeutics.

Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease

A. Ford, L. Peyrin-Biroulet, J. Bronowicki, 2014, Alimentary pharmacology & therapeutics.

Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

A. Ford, S. Halpin, 2012 .

Irritable bowel syndrome

A. Ford, N. Talley, B. Lacy, 2005, The New England journal of medicine.

Breath testing and antibiotics for possible bacterial overgrowth in irritable bowel syndrome

A. Ford, 2010, Expert review of anti-infective therapy.

Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis

A. Ford, P. Schoenfeld, D. Brenner, 2013, The American Journal of Gastroenterology.

Meta‐analysis: coeliac disease and hypertransaminasaemia

A. Ford, A. Sainsbury, A. Ford, 2011, Alimentary pharmacology & therapeutics.

Central pain processing in irritable bowel syndrome is modulated by mood: a mechanism for the beneficial effects of antidepressants?

A. Ford, R. Sood, 2015, Gastroenterology.

VSL#3 in Postoperative Crohn's Disease.

A. Ford, T. Manship, 2015, Clinical Gastroenterology and Hepatology.

Response to Levenstein and Prantera

A. Ford, D. Gracie, P. Hamlin, 2016, The American Journal of Gastroenterology.

Validation and modification of a diagnostic scoring system to predict microscopic colitis

A. Ford, D. Gracie, J. Kane, 2016, Scandinavian Journal of Gastroenterology.

Title: Validation and Modification of a Diagnostic Scoring System to Predict Microscopic Colitis. Short title: Validating and Modifying a Scoring System for Microscopic Colitis

Natalie, A. Ford, D. Gracie, 2016 .

Mo1635 Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience

A. Ford, A. Rej, A. Agrawal, 2016 .

Polyethylene Glycol in Constipation-Predominant Irritable Bowel Syndrome

A. Ford, J. Shearer, 2014, The American Journal of Gastroenterology.

Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?

A. Ford, N. Talley, B. Lacy, 2018, The American Journal of Gastroenterology.

Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach

P. Nachev, A. Ford, A. Farmer, 2021 .

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

P. Moayyedi, A. Ford, L. Brandt, 2008, Gut.

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

A. Ford, L. Peyrin-Biroulet, 2013, The American Journal of Gastroenterology.

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial)

P. Moayyedi, A. Ford, B. Delaney, 2008, BMJ : British Medical Journal.

Systematic review with meta‐analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea

A. Ford, A. Farmer, Q. Aziz, 2015, Alimentary pharmacology & therapeutics.

Reply.

A. Ford, D. Gracie, 2018, Gastroenterology.

Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.

A. Ford, D. Gracie, P. Hamlin, 2017, The lancet. Gastroenterology & hepatology.

TITLE PAGE Title: Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-reporting Behavior Rather than Biochemical Activity or Anemia. Short Title: Fatigue in IBD: Influencing factors. Authors: Raguprakash Ratnakumaran

R. Ratnakumaran, A. Ford, D. Gracie, 2018 .

Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation?

A. Ford, D. Gracie, 2017, Inflammatory bowel diseases.

High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria.

A. Ford, D. Sanders, Imran Aziz, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions.

P. Moayyedi, A. Ford, P. Bercik, 2014, Gastroenterology.

Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents

A. Ford, A. Sainsbury, 2011, Therapeutic advances in gastroenterology.

Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis

P. Moayyedi, A. Ford, N. Talley, 2008, Gut.

Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study.

A. Garg, P. Moayyedi, A. Ford, 2010, Gastroenterology.

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome.

A. Ford, C. Black, A. Tuteja, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The natural history of gastro‐oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10‐year follow‐up study

D. Forman, P. Moayyedi, A. Ford, 2013, Alimentary pharmacology & therapeutics.

Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease.

A. Ford, D. Gracie, 2017, Gastroenterology.

Eradicating Helicobacter pylori in functional dyspepsia.

A. Ford, 2012, Gastroenterology.